David A Cox

Q: What Schools Are Affiliated With David A Cox

David A Cox is affiliated with the following schools: Wake Forest University, Icahn School of Medicine at Mount Sinai, Princeton University, Columbia University, Duke University, Harvard University

David A Cox's AcademicInfluence.com Rankings

David A Cox

Mathematics

#7532

World Rank

#10227

Historical Rank

Algebraic Geometry

#167

World Rank

#174

Historical Rank

Measure Theory

#2258

World Rank

#2707

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Why Is David A Cox Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David A Cox's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. (2004) (2858)
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. (2002) (1310)
Bivalirudin for patients with acute coronary syndromes. (2006) (1122)
Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction (1999) (915)
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial (2004) (796)
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. (2001) (751)
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study (2013) (734)
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. (2005) (558)
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. (2005) (514)
Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women (2005) (493)
Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. (1990) (470)
Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. (1989) (452)
Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction (2003) (417)
Percutaneous Recanalization of Chronically Occluded Coronary Arteries: A Consensus Document Part II (2005) (411)
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. (2007) (410)
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial (2007) (392)
Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts (2003) (389)
Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial (2002) (374)
Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. (2000) (363)
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. (2000) (358)
Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial (2005) (341)
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. (2002) (331)
Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. (2005) (322)
Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. (2015) (315)
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. (2007) (304)
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. (2012) (298)
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Study (2014) (284)
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. (2007) (267)
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. (2004) (254)
Cognitive function in postmenopausal women treated with raloxifene. (2001) (234)
Salvage of Myocardial Function by Coronary Artery Reperfusion 1, 2, and 3 Hours after Occlusion in Conscious Dogs (1983) (230)
Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial (2004) (228)
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study (2013) (224)
Usefulness of a cobalt chromium coronary stent alloy. (2003) (206)
Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. (2004) (198)
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. (2005) (197)
Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial (2009) (197)
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (193)
Selectivity of inhibition of Na(+)-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157. (1993) (193)
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2005) (190)
Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. (1996) (187)
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. (2004) (187)
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (176)
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. (2005) (173)
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. (2008) (166)
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2003) (161)
Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). (2007) (159)
A role for the mitochondrial Na(+)-Ca2+ exchanger in the regulation of oxidative phosphorylation in isolated heart mitochondria. (1993) (159)
Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). (2000) (156)
Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. (2005) (153)
Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). (2001) (152)
Early evidence of endothelial vasodilator dysfunction at coronary branch points. (1990) (151)
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. (2006) (148)
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women (1999) (148)
Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. (2007) (143)
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. (2006) (136)
Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction: Results From the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial (2004) (135)
Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). (2009) (135)
Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results (2005) (129)
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. (2005) (127)
Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial (2010) (111)
Modulation of intramitochondrial free Ca2+ concentration by antagonists of Na(+)-Ca2+ exchange. (1993) (111)
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. (2006) (110)
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. (2005) (104)
Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial (2001) (104)
Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). (2007) (102)
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women (2011) (96)
Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. (2004) (93)
Defining the length of stay following percutaneous coronary intervention (2009) (93)
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. (2004) (89)
Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. (2001) (86)
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. (2008) (85)
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2010) (85)
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (83)
Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. (2004) (83)
Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. (2005) (82)
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2009) (81)
Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. (2009) (80)
Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. (2009) (79)
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). (2006) (78)
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. (2006) (78)
Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. (1998) (78)
Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. (2001) (77)
Risk‐Benefit Profile for Raloxifene: 4‐Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial (2004) (76)
Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial). (2003) (70)
Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. (2006) (69)
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (68)
Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). (2004) (68)
Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. (2017) (67)
Reflex increase in blood pressure during the intracoronary administration of adenosine in man. (1989) (66)
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. (2005) (65)
Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry (2015) (64)
The antihypertensive effects of doxazosin: a clinical overview. (1986) (64)
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. (2003) (64)
Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. (1987) (64)
Selective estrogen receptor modulators: tissue actions and potential for CNS protection. (2006) (63)
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. (2013) (58)
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. (2006) (57)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) (2021) (57)
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. (2010) (56)
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). (2005) (56)
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. (2006) (55)
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. (2013) (54)
A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy (2017) (54)
Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. (2006) (54)
Raloxifene and risk for stroke based on the framingham stroke risk score. (2009) (49)
Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). (2014) (49)
Coronary heart disease in women, randomized clinical trials, HERS and RUTH. (1998) (48)
Usage patterns and 2‐year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry (2008) (46)
Myocardial Function in Areas of Heterogeneous Perfusion After Coronary Artery Occlusion in Conscious Dogs (1982) (45)
Effects of acetylcholine on large and small coronary arteries in conscious dogs. (1983) (44)
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene (2012) (43)
Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. (2007) (42)
Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. (2005) (41)
Effect of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries (1992) (41)
Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study (2015) (41)
Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial (2003) (41)
5-Hydroxytryptamine2B receptor signaling in rat stomach fundus: role of voltage-dependent calcium channels, intracellular calcium release and protein kinase C. (1995) (40)
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). (2004) (39)
Clinically guided closure of femoral arterial pseudoaneurysms complicating cardiac catheterization and coronary angioplasty. (1993) (38)
Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. (2007) (37)
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies (2014) (37)
Extracellular matrix integrity: A possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? (2006) (36)
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (2014) (36)
The Potential of SERMs for Reducing the Risk of Coronary Heart Disease (1999) (36)
Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. (2006) (36)
Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2012) (35)
Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. (2009) (34)
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial (2011) (34)
Percutaneous Recanalization of Chronically Occluded Coronary Arteries A New Drugs and Technologies (2005) (33)
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials (2019) (33)
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. (2016) (33)
A clinical risk score for prediction of stent thrombosis. (2008) (32)
Therapeutic Hypothermia and Stent Thrombosis: A Nationwide Analysis. (2016) (32)
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). (2015) (32)
Does proximal location of culprit lesion confer worse prognosis in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction? (2006) (31)
Effect of Raloxifene on all-cause mortality. (2010) (31)
Asymptomatic Cardiac Ischemia Pilot study (ACIP) (1992) (31)
One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty. (2003) (30)
Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: Results from the multicenter X‐sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X‐TRACT) study (2003) (30)
Clinical Decision Making Defining the Length of Stay Following Percutaneous Coronary Intervention: An Expert Consensus Document From the Society for Cardiovascular Angiography and Interventions (2009) (29)
5-HT2B receptor signaling in the rat stomach fundus: dependence on calcium influx, calcium release and protein kinase C (1995) (29)
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. (2017) (29)
829-5 Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: Principal results from the prospective, randomized EMERALD trial (2004) (28)
Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. (2000) (28)
Selective enhancement of 5-hydroxytryptamine-induced contraction of porcine coronary artery by oxidized low-density lipoprotein. (1996) (28)
Lysophosphatidylcholine stimulates phospholipase D in human coronary endothelial cells: role of PKC. (1996) (27)
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) (2017) (27)
Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. (2000) (26)
One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial. (2001) (25)
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. (2016) (25)
Contractile serotonin-2A receptor signal transduction in guinea pig trachea: importance of protein kinase C and extracellular and intracellular calcium but not phosphoinositide hydrolysis. (1994) (24)
Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. (2009) (24)
Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients (2009) (24)
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: Two-Year Follow-Up of the ADAPT-DES Study (2018) (23)
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. (2003) (22)
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection (2006) (21)
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis (2012) (20)
Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. (2016) (19)
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. (2015) (19)
A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial (2001) (19)
TCT-21 Use of IVUS Reduces Stent Thrombosis: Results from the Prospective, multicenter ADAPT-DES Study (2012) (19)
Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. (2007) (19)
Influence of Atrial Fibrillation on Outcomes in Patients Who Underwent Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. (2017) (19)
Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction. (2003) (19)
Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. (2001) (19)
Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. (2017) (18)
Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). (2008) (17)
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). (2016) (17)
Relationship between phospholipase D activation and endothelial vasomotor dysfunction in rabbit aorta. (1997) (17)
Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. (2010) (17)
Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study (2015) (17)
Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial. (2010) (17)
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. (2004) (17)
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). (2017) (17)
Cardiac Imaging in the Post-ISCHEMIA Trial Era: A Multisociety Viewpoint. (2020) (16)
Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. (2001) (16)
Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. (2014) (16)
A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients. (2011) (16)
Amyloid β-induced neurotoxicity is associated with phospholipase D activation in cultured rat hippocampal cells (1997) (15)
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population: Analysis From the ADAPT-DES Registry (2018) (15)
Influence of gender on vasomotor effects of oxidized low-density lipoprotein in porcine coronary arteries. (1997) (15)
Identification of a 17-kDa protein associated with the peripheral-type benzodiazepine receptor in vascular and other smooth muscle types. (1991) (15)
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial) (2003) (14)
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration (2020) (14)
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11 (2021) (14)
Cardiac procedural deferral during the coronavirus (COVID‐19) pandemic (2020) (14)
Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). (2004) (14)
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin (2019) (14)
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. (2018) (13)
Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. (2007) (13)
Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. (1994) (13)
SCAI multi‐society position statement on occupational health hazards of the catheterization laboratory: Shifting the paradigm for Healthcare Workers' Protection (2020) (12)
Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass (2010) (12)
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass (2012) (12)
Prognostic implications of an early peak in plasma MB creatine kinase in patients with acute myocardial infarction. (1987) (12)
Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. (2009) (12)
Implications of myocardial reperfusion on survival in women versus men with acute myocardial infarction undergoing primary coronary intervention. (2013) (11)
Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). (2005) (11)
A comparative analysis of primary stenting and optimal balloon coronary angioplasty in acute myocardial infarction. Six month results from the STENT PAMI trial. (2000) (11)
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. (2022) (11)
Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. (1998) (10)
Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). (2003) (10)
Neomycin selectively inhibits 5-hydroxytryptamine-induced contraction in the guinea pig trachea. (1996) (9)
Improved quality of life after successful balloon valvuloplasty of a stenosed mitral bioprosthesis. (1989) (9)
A prospective, randomized trial of bivaliruclin in acute coronary syndromes: One year results from the ACUITY Trial (2007) (8)
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. (2021) (8)
Acute myocardial infarction with normal coronary arteries associated with acetylcholine-induced vasoconstriction in the absence of a positive ergonovine test. (1990) (8)
SCAI Multi-Society Position Statement on Occupational Health Hazards of the Catheterization Laboratory: Shifting the Paradigm for Healthcare Workers' Protection. (2020) (8)
SCAI publications committee manual of standard operating procedures (2020) (8)
Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial. (2013) (7)
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). (2003) (7)
Variation in hospital length of stay in patients with acute myocardial infarction undergoing primary angioplasty and the need to change the diagnostic-related group system. (2003) (7)
Effects of Coronary Artery Reperfusion on Recovery of Regional Myocardial Function In Conscious Dogs (1985) (7)
How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial (2003) (7)
IMPACT OF POINT–OF–CARE PLATELET FUNCTION TESTING AMONG PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROMES UNDERGOING PCI WITH DRUG–ELUTING STENTS: AN ADAPT–DES SUBSTUDY (2012) (6)
Abstract 4949: Bleeding and Ischemic Complications in Patients With Acute Coronary Syndromes and Chronic Kidney Disease in Relation to Different Glycoprotein IIb/IIIa Inhibitors: Analysis From the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial (2009) (6)
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study). (2019) (6)
Impact of high on‐aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug‐eluting stents (2018) (6)
DOES PLATELET FUNCTION TESTING ADD SIGNIFICANT INCREMENTAL RISK STRATIFICATION TO UNSELECTED PATIENTS UNDERGOING DES IMPLANTATION? THE ADAPT-DES STUDY (2012) (6)
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial (2008) (6)
Impact of high on‐treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT‐DES substudy (2019) (6)
Bradykinin and phorbol ester but not 5-HT2B receptor activation stimulate phospholipase D activity in the rat stomach fundus (1999) (6)
Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women (2004) (6)
5-HT 2 B receptor signaling in the rat stomach fundus : dependence on calcium influx , calcium release and protein kinase C (6)
357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11 (2020) (5)
Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. (2005) (5)
Control of shear stress in the epicardial coronary arteries of humans: impairment by atherosclerosis. (1989) (5)
Myocardium salvaged by coronary artery reperfusion responds appropriately to cardiovascular stress. (1981) (5)
Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program. (2011) (4)
Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries. (2011) (4)
A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities (2021) (4)
Antiplatelets and AntithrombinsTCT-152 Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study (2013) (4)
Is nitric oxide involved in 5-HT2B receptor-mediated contraction in the rat stomach fundus? (1995) (4)
Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). (2003) (4)
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. (2009) (4)
Multiple lesion coronary intervention is associated with higher mortality in primary angioplasty for acute myocardial infarction: The stent PAMI trial (2003) (3)
Magnitude and impact of after hours treatment delay in patients undergoing primary angioplasty for acute myocardial infarction: The CADILLAC Trial (2003) (3)
Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass (2010) (3)
Are adverse events following an invasive strategy in patients with non‐ST‐segment elevation acute coronary syndromes more frequent at US sites versus Non‐US sites? analysis from the ACUITY trial (2013) (3)
Effects of Arzoxifene on Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Mass. (2009) (3)
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial (2021) (3)
1002-82 Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction: The obesity paradox (2004) (2)
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions 2020 think tank (2020) (2)
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug‐Eluting Stents (ADAPT‐DES) study (2019) (2)
Endovascular repair of ruptured pseudoaneurysm of left internal mammary graft following redo aortic valve replacement and coronary artery bypass grafting. (2015) (2)
Early and late results of thrombectomy prior to stenting in acute myocardial infarction: principal report of the EndiCOR X-SIZER AMI registry (2002) (2)
Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial (2002) (2)
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutancous coronary intervention: One year results from the randomized ACUITY trial (2007) (2)
Effects of Myocardial Ischemia on Regional Myocardial Function in the Experimental Animal (1985) (2)
First use of a novel cobalt chromium coronary stent in humans: Clinical and angiographic outcomes (2003) (2)
Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on target vessel revascularization in diabetics after primary PCI in acute myocardial infarction: the CADILLAC trial (2002) (2)
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11 (2021) (2)
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. (2004) (2)
Antiplatelets and AntithrombinsTCT-157 The Effect of Smoking Status on Platelet Reactivity and Long-Term Events after PCI. Does a Clopidogrel-related "Smoker's paradox" Exist? (2013) (2)
1245 EFFECTS OF TADALAFIL OR TAMSULOSIN ON LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA AND ON ERECTILE DYSFUNCTION: RESULTS FROM AN INTERNATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (2012) (2)
A prospective randomized multicenter trial comparing distal protection during saphenous vein graft intervention with a filter-based device compared to balloon occlusion and aspiration: The FIRE trial (2003) (2)
A prospective, randomized trial of thromboatherectomy during intervention of thrombotic native coronary arteries and saphenous vein grafts: The X-TRACT trial (2003) (1)
Effects of acetylcholine on large coronary vessels in conscious dogs (1981) (1)
TCT-486 Additive And Independent Impact Of Chronic Kidney Disease And Diabetes Mellitus On High Platelet Reactivity And Adverse Events Following PCI: Results From The ADAPT-DES Registry (2014) (1)
IMPACT OF PRIOR CHRONIC ANTIPLATELET THERAPY ON SHORT- AND LONG-TERM ADVERSE EVENTS IN PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ACUITY TRIAL (2010) (1)
Interventional Cardiology AbstractsOutcomes of optimal or “stent-like” balloon angioplasty in acute myocardial infarction: the CADILLAC trial (2004) (1)
Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: An analysis from the CADILLAC trial (2003) (1)
Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction (2016) (1)
Efficacy and Safety of an Expanded Dulaglutide Dose Range—A Phase 2, Placebo-Controlled Trial in T2D Patients on Metformin (2018) (1)
Primary Coronary Intervention: The Technical Approach (2009) (1)
Composite confusion. Autor's reply (2004) (1)
Arzoxifene versus raloxifene: 12-month effects on bone mineral density, bone turnover markers, and safety parameters in postmenopausal women with osteoporosis (2009) (1)
Time course of vulnerability to reperfusion-induced ventricular fibrillation (1981) (1)
IS PLATELET REACTIVITY ASSOCIATED WITH ISCHEMIC EVENTS FOLLOWING SUCCESSFUL CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION (2017) (1)
EVALUATION OF THIENOPYRIDINE COMPLIANCE AND STENT THROMBOSIS RATES AFTER EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENT IMPLANTATION: 3-YEAR RESULTS FROM THE SPIRIT III ANALYSIS (2010) (1)
Late angiographic and clinical findings after elective placement of the penta stent: results from the PENTA stent registry (2002) (1)
Prostatic Diseases and Male Voiding Dysfunction EfficacyandSafetyofTadalafil5mgOnceDaily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies (2013) (1)
5-LB: Dulaglutide in Youth with Type 2 Diabetes (T2D) —Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial (2022) (1)
Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply. (2022) (1)
TCT-479 The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes is Confined to the First 30 days After PCI: Results from the Multicenter ADAPT-DES Study (2014) (1)
SCAI 2018 Think Tank Proceedings: “What should the role of the surgeon be in TAVR, both as a co‐operator and in‐patient evaluation for TAVR? (2018) (1)
TAXUS-IV trial proliferation: A serial volumetric intravascular ultrasound analysis from the Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue (2011) (1)
830-5 The impact of myocardial blush grade on clinical outcomes of patients treated with saphenous vein grafts and thrombotic native coronary arteries: Analysis from the X-TRACT trial (2004) (1)
Selective Endothelial Dysfunction in Porcine Coronary Artery Produced by Incubation in Cell Culture Medium in vitro (1995) (1)
Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC Registry (2003) (1)
Trial finds paclitaxel-eluting stents reduce restenosis over bare metal stents in coronary artery disease. (2004) (1)
TCT-597 Two-Year Ischemic and Bleeding Outcomes After Coronary Intervention of Calcified vs. Non-Calcified Lesions Treated With Drug-eluting Stents: The ADAPT-DES Study (2015) (1)
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). (2010) (1)
TCT-5 Relationship Between High Platelet Reactivity on Clopidogrel and Outcomes After DES Implantation: Two-Year Results From the ADAPT-DES Study (2013) (1)
RALOXIFENE THERAPY (2000) (1)
Abstract 3114: Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use in The Heart (RUTH) Trial (2007) (1)
OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11) (2020) (1)
Clinical trial evidence that raloxifene favorably affects surrogate markers of cardiovascular risk in postmenopausal women : Symposium : Cardiovascular considerations in obesity and its management (1999) (1)
Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study". (2016) (1)
What Should I Do?: Maintenance of Certification for All Cardiologists in 2019 and Beyond. (2019) (1)
TCT-6 Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results from the ADAPT-DES Registry (2013) (1)
Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. (2011) (1)
One Year Outcomes of a Pre-Hospital Myocardial Infarction Alert 3 Process (2010) (0)
Supplementary material : Influence of Atrial Fibrillation on Outcomes in Patients Who Underwent Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (2018) (0)
Comparison of heparin plus IIb/IIIa inhibition versus bivalirudin with or without IIb/IIIa inhibition in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
Drug eluting stents in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
Composite confusion: Reply (2004) (0)
TCT-23 Etiology, Frequency, and Clinical Outcomes of Post-procedural Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-up From the ADAPT-DES Study (2014) (0)
Percutaneous Coronary Intervention for Acute Myocardial Infarction Prognostic Implications of Creatine Kinase Elevation After Primary (2011) (0)
Rapid Door to Balloon Time in the Treatment of Acute ST- Elevation Myocardial Infarction Meaningfully Reduces Overall Hospital Stay (2012) (0)
An Uncommon Complication During Trans-Aortic Valve Replacement (2014) (0)
TWO-YEAR CLINICAL OUTCOMES OF SECOND GENERATION VERSUS FIRST GENERATION CORONARY DRUG-ELUTING STENTS: AN ANALYSIS FROM ADAPT-DES (2014) (0)
Spontaneous Coronary Artery Dissection: A Rare but Deadly Cause of ACS in Younger Patients (2012) (0)
Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries (2009) (0)
IMPACT OF ATRIAL FIBRILLATION ON OUTCOMES IN PATIENTS HOSPITALIZED WITH ST- SEGMENT ELEVATION MYOCARDIAL INFARCTION (2017) (0)
Poor one year prognosis in acute myocardial infarction patients with saphenous vein grafts as the infarct related vessel treated by primary balloon angioplasty (2002) (0)
TCT-353 Underweight Status, Platelet Reactivity, and 2-Year Clinical Outcomes in Patients Undergoing PCI With DES: An ADAPT-DES Study Analysis. (2016) (0)
Does optimal or stent-like PTCA provide equivalent outcomes compared to primary stenting in acute myocardial infarction? Early and late results from the CADILLAC trial (2002) (0)
Age-related alterations in sensitivity of muscarinic and serotonergic responses of guinea pig trachea to removal of extracellular Ca2+. (1994) (0)
Door to Balloon times less than 30 minutes: The Lehigh Valley Health Network (LVHN) Experience (2011) (0)
TCT-352 Proportion of Ischemic Risk After PCI Mediated by High Platelet Reactivity on Clopidogrel: Analysis From the ADAPT-DES Study. (2016) (0)
Clopidogrel pretreatment versus clopidogrel exposure prior to PCI in the ACUITY Trial: Does it really matter? (2007) (0)
Predictors and sequalae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: The CADILLAC trial (2003) (0)
mpact of Anemia in Patients With cute Myocardial Infarction Undergoing rimary Percutaneous Coronary Intervention nalysis From the Controlled Abciximab and Device (2016) (0)
How to Organize Networks for Invasive Treatment of STEMI: Experience in the United States (2010) (0)
ST-Segment Elevation (STEMI) Real Time Data Feedback –A Process of Care Initiative (2013) (0)
943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide (2020) (0)
Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial (2003) (0)
Can percutaneous coronary interventions be performed safely in leukemia patients? (2020) (0)
TCT-64 Incidence, Predictors, and Impact of Post-discharge Bleeding Compared to Myocardial Infarction After Percutaneous Coronary Intervention (2015) (0)
TCT-540 Incidence, Predictors, and Impact of Post-Discharge Gastrointestinal Bleeding After Coronary Drug-Eluting Stents Implantation: The ADAPT-DES Study (2018) (0)
olymer-Based Paclitaxel-Eluting Stents educe In-Stent Neointimal Tissue Proliferation (2005) (0)
Reply: Do We Need Individualized Therapeutic Strategies in High-Risk Patients Treated With Hypothermia? (2017) (0)
(cadillac) trial abciximab and device investigation to lower late angioplasty complications primary percutaneous coronary intervention: Analysis from the controlled Impact of anemia in patients with acute myocardial infarction undergoing (2011) (0)
DIFFERENTIAL IMPACT OF HIGH PLATELET REACTIVITY ON CLOPIDOGREL IN WOMEN AND MEN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH DES (2015) (0)
DRUG-ELUTING VERSUS BARE-METAL STENTS IN TREATMENT OF DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROMES: ANALYSIS FROM THE RANDOMIZED ACUITY TRIAL (2010) (0)
Treatment of Acute Infarction With PCI Outcomes of Optimal or “ Stent-Like ” Balloon Angioplasty in Acute Myocardial Infarction : The CADILLAC Trial (2016) (0)
Long Term STEMI Outcome Data Acquisition (2013) (0)
869-2 Impact of intravenous beta-blockade during primary percutaneous intervention on convalescent left ventricular function (2004) (0)
A closed loop system for infusion of intravenous lidocaine (1990) (0)
Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial (2003) (0)
TCT-2 Incidence and Impact of Totally Occluded Culprit Arteries in Patients with Non-ST-segment Elevation (2014) (0)
Thirty day and six month results of a multicenter randomized trial comparing distal protection with a filter-based catheter to balloon occlusion and aspiration during percutaneous intervention of saphenous vein bypass grafts the fire trial (2003) (0)
Abstract 5610: Bivalirudin in Patients with Acute Coronary Syndromes Undergoing Saphenous Vein Graft Percutaneous Coronary Intervention: A Subgroup Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial (2008) (0)
869-1 Relationship between time to reperfusion, ST-segment resolution, myocardial blush scores and mortality with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial (2004) (0)
Gender is an independent predictor of both in-hospital and one-year outcomes following primary intervention for acute myocardial infarction (2002) (0)
Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11 (2021) (0)
830-6 Relationship between embolic material retrieval and adverse events with different distal protection devices during saphenous vein graft stenting (2004) (0)
TCT-155 The Interaction Between Clopidogrel and Calcium Channel Blockers on Platelet Reactivity and Long-Term Events after PCI (2013) (0)
641 Monotherapy with tadalafil or tamsulosin for moderate-to-severe lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from an international, double-blind, placebo-controlled trial (2012) (0)
Rapid Door to Balloon Time in the Treatment of Acute ST-Elevation Myocardial Infarction is Associated with Reduced Length of Hospital Stay (2013) (0)
Optimizing Therapy for Acute Coronary Syndrome (2015) (0)
TCT-1 Do Proton Pump Inhibitors Interact With Clopidogrel? Insights From ADAPT-DES (2013) (0)
TCT-18 Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study (2013) (0)
Prognostic value of the absolute degree of ST-segment elevation of the ECG at baseline and after primary angioplasty: Analysis from the CADILLAC trial (2003) (0)
Abstract: 1057 RALOXIFENE AND STROKE RISK BASED ON THE FRAMINGHAM STROKE RISK SCORE (2009) (0)
TCT-7 Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES. (2016) (0)
TWO-YEAR OUTCOMES AFTER UTILIZATION OF THE TAXUS PACLITAXEL-ELUTING STENT IN BIFURCATIONS AND MULTIVESSEL STENTING IN THE ARRIVE REGISTRIES (2011) (0)
utcomes After Implantation of the AXUS Paclitaxel-Eluting Stent in Saphenous ein Graft Lesions esults From the ARRIVE ( TAXUS Peri-Approval Registry : Multicenter Safety Surveillance ) Program mmanouil (0)
IMPACT OF HEMODIALYSIS AND HIGH PLATELET REACTIVITY ON OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS: AN ADAPT-DES SUBSTUDY (2014) (0)
801-3 Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial (2004) (0)
1155-78 Implications and prevention of large periprocedural myocardial infarction after percutaneous intervention of diseased saphenous vein grafts and thrombotic native coronary lesions (2004) (0)
1061-100 Predictors of reinfarction after ST elevation myocardial infarction and glycoprotein receptor blockade: Analysis from the CADILLAC trial (2004) (0)
TCT-237 Outcomes After Successful PCI of Severely Calcified Lesions Using Rotational Atherectomy, Cutting Balloon, or Balloon Angioplasty only Before Second-Generation Drug-Eluting Stent Implantation. (2016) (0)
Primary Coronary Intervention for Acute Myocardial Infarction (2002) (0)
TCT-8 Impact of Aspirin Resistance on Outcomes after Coronary Events. (2016) (0)
705 Effects of tadalafil (TAD) or tamsulosin (TAM) on erectile function in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Results from a multicenter, double-blind, randomized, placebo (PLA)-controlled 12-week study (2012) (0)
778 Satisfaction with tadalafil or tamsulosin once daily for the treatment of LUTS/BPH: Treatment satisfaction scale questionnaire results from a randomized double-blind, placebo-controlled trial (2014) (0)
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction ☆ (2002) (0)
IMPACT OF ANTITHROMBOTIC REGIMEN AND TROPONIN STATUS ON OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES: THE ACUITY TRIAL (2010) (0)
ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: The CADILLAC trial (2003) (0)
mpact of Intravenous Beta-Blockade efore Primary Angioplasty on Survival n Patients Undergoing Mechanical eperfusion Therapy for Acute Myocardial Infarction (2016) (0)
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. (2016) (0)
Abstract 2560: Stent Thrombosis Predictors in Everyday Practice: Insights from the 7000-Patient TAXUS ARRIVE Registry Program (2007) (0)
Abstract 4589: Anti-thrombotic Strategies in Patients with Elevated Biomarkers Undergoing PCI: Results from the ACUITY Trial (2008) (0)
Primary Coronary Intervention for Acute Myocardial Infarction: Technical Approaches (2002) (0)
On‐Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two‐Year Results From ADAPT‐DES (2022) (0)
Antiplatelets and AntithrombinsTCT-156 Impact of Clopidogrel Hyporesponsiveness on Clinical Outcomes in Patients Receiving Drug-eluting Stents for Stable Coronary Disease in the ADAPT-DES Study (2013) (0)
Does abciximab and stenting improve outcomes in elderly patients undergoing primary PCI for acute myocardial infarction: data from the CADILLAC trial (2002) (0)
Comparison of catheterization lab initiated abciximab and double-bolus eptifibatide during percutaneous coronary intervention in acute coronary syndromes: an ACUITY substudy (2007) (0)
801-2 Predictors of survival after primary percutaneous coronary intervention: The impact of myocardial perfusion grade in female patients (2004) (0)
TCT-546 Performance of the Dual AntiPlatelet Therapy (DAPT) Score in the ADAPT-DES Study. (2017) (0)
TCT-400 Platelet Reactivity and Risk of Stent Thrombosis After Coronary Drug-Eluting Stent Implantation in Patients Treated With Oral Anticoagulation: The ADAPT-DES Study (2019) (0)
830-3 Impact of vessel size on outcomes of different distal protection devices during saphenous vein graft intervention: A FIRE trial substudy (2004) (0)
Outcome after acute myocardial infarction in young patients: analysis of the PAMI database (2002) (0)
1063-64 Predilatation before distal protection device placement is associated with increased procedure-related myocardial infarction: Analysis from the FIRE trial (2004) (0)
92: Out-of-Hospital Electrocardiogram Interpretation and Early Activation for ST-Segment Elevation Myocardial Infarction Patients Reduces Door-to-Balloon Times and Hospital Length of Stay (2009) (0)
Outcomes in patients requiring bail-out abciximab during primary intervention in acute myocardial infarction: Analysis from the CADILLAC trial (2003) (0)
Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction (2003) (0)
116: Impact of Out-of-Hospital Myocardial Infarction Alert Process Education on Door to Balloon Times at Sites Within a Regional Heart Center (2010) (0)
207: One-Year Outcomes of an Out–of–Hospital Myocardial Infarction Alert 3 Process (2010) (0)
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IS ASSOCIATED WITH A HIGHER RATE OF PERMANENT PACEMAKER IMPLANTATION COMPARED TO SURGICAL AORTIC VALVE REPLACEMENT (SAVR): A PROPENSITY MATCHED ANALYSIS (2016) (0)
TCT-483 Impact of HbA1c Levels on Residual Platelet Reactivity and Outcomes after Coronary Drug-Eluting Stents: The ADAPT-DES study (2014) (0)
680-P: Once-Weekly Dulaglutide 3 mg and 4.5 mg Gastrointestinal Tolerability: Post-hoc Analysis of Incidence and Prevalence in Award-11 (2021) (0)
Efficacy of investigational dulaglutide doses overall and by baseline HbA1c and Body Mass Index (BMI): exploratory subgroup analyses of the AWARD-11 trial (2021) (0)
ESICON 2018 Abstracts (2018) (0)
Author response for "Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg in patients age < 65 and ≥ 65 years: post hoc analysis of the AWARD‐11 trial" (2021) (0)
651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11 (2021) (0)
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study (2022) (0)
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11 (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David A Cox?

David A Cox is affiliated with the following schools:

Wake Forest University
Icahn School of Medicine at Mount Sinai
Princeton University
Columbia University
Duke University
Harvard University

David A Cox's Academic­Influence.com Rankings

Why Is David A Cox Influential?

David A Cox's Published Works

Published Works

What Schools Are Affiliated With David A Cox?

David A Cox's AcademicInfluence.com Rankings